{
    "clinical_study": {
        "@rank": "21719", 
        "arm_group": [
            {
                "arm_group_label": "SIMBRINZA\u2122", 
                "arm_group_type": "Experimental", 
                "description": "Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension, 1 drop instilled 3 times a day in each eye for 6 weeks as adjunctive therapy to prostaglandin analogue"
            }, 
            {
                "arm_group_label": "Vehicle", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Inactive ingredients, 1 drop instilled 3 times a day in each eye for 6 weeks in conjunction with prostaglandin analogue"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to demonstrate the additive effect of brinzolamide\n      1%/brimonidine 0.2% (SIMBRINZA\u2122) in subjects with either open angle glaucoma or ocular\n      hypertension who are currently on a prostaglandin analogue (PGA) monotherapy."
        }, 
        "brief_title": "Effect of SIMBRINZA\u2122 As an Added Therapy to a Prostaglandin Analogue", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Ocular Hypertension", 
            "Open Angle Glaucoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Glaucoma, Open-Angle", 
                "Hypertension", 
                "Ocular Hypertension"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study is divided into 2 sequential phases. The Screening/Eligibility phase includes one\n      screening visit and two eligibility visits, during which subjects will washout of all other\n      IOP-lowering medications and dose with TRAVATAN Z\u00ae, XALATAN\u00ae, or LUMIGAN\u00ae, 1 drop instilled\n      in each eye once daily for 28 days. Subjects who meet all inclusion/exclusion criteria will\n      be randomized at the second eligibility visit. The Treatment phase consists of two\n      on-therapy visits (Week 2 and Week 6)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of open angle glaucoma (including open-angle glaucoma with\n             pseudoexfoliation or pigment dispersion) or ocular hypertension;\n\n          -  Mean intraocular pressure (IOP) measurements in at least 1 eye (study eye) of \u2265 21\n             mmHg and <32 mmHg at 2 consecutive visits (Eligibility 1 and Eligibility 2);\n\n          -  Able to understand and sign Informed Consent Document;\n\n          -  Other protocol-defined inclusion criteria may apply.\n\n        Exclusion Criteria:\n\n          -  Women of childbearing potential who are pregnant, breastfeeding, or do not agree to\n             use an adequate birth control method throughout the study;\n\n          -  Any form of glaucoma other than open angle glaucoma or ocular hypertension;\n\n          -  Severe central visual field loss;\n\n          -  Chronic, recurrent, or severe inflammatory eye disease;\n\n          -  Ocular trauma within the past 6 months;\n\n          -  Ocular infection or ocular inflammation within the past 3 months;\n\n          -  Best-corrected visual acuity score worse than approximately 20/80 Snellen;\n\n          -  Eye surgery within the past 6 months;\n\n          -  Any condition, including severe illness, which would make the subject unsuitable for\n             the study in the opinion of the Investigator;\n\n          -  Use of any additional topical or systemic ocular hypertensive medication during the\n             study;\n\n          -  Patients who, in the opinion of the Investigator, cannot discontinue all IOP-lowering\n             ocular medication(s) per the appropriate washout schedule prior to Eligibility 1\n             Visit;\n\n          -  Other protocol-defined exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "282", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01937312", 
            "org_study_id": "M-13-020"
        }, 
        "intervention": [
            {
                "arm_group_label": "SIMBRINZA\u2122", 
                "intervention_name": "Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension", 
                "intervention_type": "Drug", 
                "other_name": "SIMBRINZA\u2122"
            }, 
            {
                "arm_group_label": "Vehicle", 
                "description": "Inactive ingredients used as a placebo comparator", 
                "intervention_name": "Vehicle", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "SIMBRINZA\u2122", 
                    "Vehicle"
                ], 
                "description": "1 drop instilled once daily in each eye for 6 weeks", 
                "intervention_name": "Prostaglandin analogue ( TRAVATAN Z\u00ae ,  LUMIGAN\u00ae, XALATAN\u00ae)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "TRAVATAN Z\u00ae", 
                    "LUMIGAN\u00ae", 
                    "XALATAN\u00ae"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Brimonidine", 
                "Latanoprost", 
                "Travoprost", 
                "Bimatoprost", 
                "Brinzolamide"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "glaucoma", 
            "prostaglandin analogue", 
            "brinzolamide", 
            "brimonidine"
        ], 
        "lastchanged_date": "May 28, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Fort Worth", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "76134"
                }, 
                "name": "Contact Alcon Call Center for Trial Locations"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Additive Effect of Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination as Adjunctive Therapy to a Prostaglandin Analogue", 
        "overall_official": {
            "affiliation": "Alcon Research", 
            "last_name": "Steve Burmaster, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Diurnal IOP is defined as the mean of the four timepoints measured (8 AM, 10 AM, 3 PM, and 5 PM). IOP will be measured by Goldmann applanation tonometry  and reported in millimeters mercury (mmHg). A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage).", 
            "measure": "Mean Diurnal Intraocular Pressure (IOP)", 
            "safety_issue": "No", 
            "time_frame": "Week 6"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01937312"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Diurnal IOP is defined as the mean of the four timepoints measured (8 AM, 10 AM, 3 PM, and 5 PM). IOP will be measured by Goldmann applanation tonometry  and reported in millimeters mercury (mmHg). A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage).", 
                "measure": "Change from Baseline in Mean Diurnal IOP at Week 6", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 6"
            }, 
            {
                "description": "Diurnal IOP is defined as the mean of the four timepoints measured (8 AM, 10 AM, 3 PM, and 5 PM). IOP will be measured by Goldmann applanation tonometry  and reported in millimeters mercury (mmHg). A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage).", 
                "measure": "Percentage Change from Baseline in Mean Diurnal IOP at Week 6", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 6"
            }
        ], 
        "source": "Alcon Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alcon Research", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}